Illumina Inc (ILMN)
187.35
+3.23 (+1.75%)
USD |
NASDAQ |
Sep 27, 15:51
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 29.47B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -57.46% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.249 |
| Price to Book Value | 2.822 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1666 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 66.23% |
News
Headline
Wire
Time (ET)
Yahoo
09/26 09:15
PR Newswire
09/22 11:00
Yahoo
09/21 07:02
Yahoo
09/20 13:53
Yahoo
09/20 11:05
PR Newswire
09/20 09:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/04/2022* | -- | Results | Q3 2022 | -- | 0.31 | -- | |
| 11/04/2022* | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/11/2022 | -- | Results | Q2 2022 | 0.57 | 0.64 | -11.56% | |
| 08/11/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | 1.07 | 0.89 | 20.78% | |
| 05/05/2022 | 17:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/10/2022 | -- | Results | Q4 2021 | 0.75 | 0.49 | 54.51% | |
| 02/10/2022 | 17:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
| URL | https://www.illumina.com |
| Investor Relations URL | https://investor.illumina.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Nov. 04, 2022 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 26, 2022.
Fundamentals
| Revenue (TTM) | 4.692B |
| Total Expenses (TTM) | 4.982B |
| Net Income (TTM) | -20.00M |
| Total Assets (Quarterly) | 15.45B |
| Total Liabilities (Quarterly) | 5.004B |
| Shareholders Equity (Quarterly) | 10.44B |
| Cash from Operations (TTM) | 307.00M |
| Cash from Investing (TTM) | -2.687B |
| Cash from Financing (TTM) | -507.00M |
Ratings
Profile
Edit
| Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
| URL | https://www.illumina.com |
| Investor Relations URL | https://investor.illumina.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Nov. 04, 2022 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| HQL | 24.54M USD | 5.02% |
| BBH | 18.25M USD | 4.42% |
| EGFFX | 841.18M USD | 4.38% |
| HQH | 44.28M USD | 4.35% |
| BMO78213 | 53.02M USD | 4.21% |
| FBT | 43.15M USD | 3.53% |
| IBB | 230.69M USD | 3.12% |
| ZCG.TO | 57.54M USD | 2.88% |
| LGRCX | 221.98M USD | 1.96% |
| VWIGX | 717.17M USD | 1.68% |
| POLRX | 128.79M USD | 1.34% |
| VWUSX | 232.71M USD | 0.72% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ILMN Tweets |